GlassScriptPhysician profile
Calah Clayton
NPI 1285129775
$4,592.75
in general payments reported to CMS, 2019-2025
16 companies · $792 in 2025
The $792 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $211 · 2021: $363 · 2022: $1,974 · 2023: $456 · 2024: $497 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701 · Education: $44.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.17 |
| Education | $44.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,296.91 | 2019-2025 | Acuvue |
| Coopervision INC. | $869.39 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $321.20 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $300.41 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $272.85 | 2020-2025 | Eysuvis, Tryptyr, Precision7 |
| Sun Pharmaceutical Industries INC. | $147.31 | 2022-2025 | Cequa |
| Oyster Point Pharma, INC. | $71.95 | 2022-2024 | Ryzumvi, Tyrvaya |
| Apellis Pharmaceuticals, INC. | $66.04 | 2025 | Syfovre |
| Dompe US, INC. | $54.05 | 2022-2024 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $50.64 | 2019 | |
| Harrow Eye, LLC | $33.21 | 2024 | Vevye |
| Abbvie INC. | $25.85 | 2023 | Vuity, Lumigan |
| Thea Pharma INC. | $22.98 | 2023 | |
| Novartis Pharmaceuticals Corporation | $22.13 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.74 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $16.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calah Clayton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.